Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression
Recent studies have shown that there are systematic differences among total and free prostate-specificantigen (PSA) immunoassays. In this study we analyzedintermethod differences in total PSA (tPSA) and free PSA(fPSA) measurement using ARCHITECT i2000SR (Abbott Diagnostics) and COBAS E601 (Roche Diagnostics). A number of 160 blood samples were tested for tPSA and 50 samples for fPSA (selecting only sampleswith tPSA: 4.1–10.0 μg/L). Passing–Bablok regression analysis was used to compare the two analytical methods fortPSA, fPSA and percentage of fPSA (%fPSA). A strong correlation was noticed between ARCHITECT i2000SR and COBAS E601 for tPSA, fPSA and %fPSA (r between 0.94 and 0.99). Concentrations of tPSA and fPSA measured by COBAS E601 were higher thanthose measured by ARCHITECT i2000SR with a bias of 0.8 μg/L for tPSA and 0.14 μg/L for fPSA. Analyzing therelative difference between methods for fPSA and %fPSA, COBAS E601 exceed a 10% relative difference limit. Our study confirms that there are differences in measured concentrations of tPSA and fPSA byvarious commercial methods. Because clinical judgment on subsequent diagnostic procedures, such as prostatebiopsy, is based on tPSA and fPSA results, tests harmonization should be a priority.
KeywordsTotal PSA Free PSA Immunoassay Method comparison Quality control
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Chistiakov DA, Myasoedova VA, Grechko AV, Melnichenko AA, Orekhov AN. New biomarkers for diagnosis and prognosis of localized prostate cancer. Semin Cancer Biol. 2018;52(Pt 1):9–16. pii: S1044-579X(17)30288. https://doi.org/10.1016/j.semcancer.2018.01.012.
- 3.Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O. A complex between prostate specific antigen and alpha-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51(1):222–6.PubMedGoogle Scholar
- 7.Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease; a prospective multicenter clinical trial. JAMA. 1998;279(19):1542–7. https://doi.org/10.1001/jama.279.19.1542.PubMedCrossRefGoogle Scholar
- 11.Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452–5. https://doi.org/10.1001/jama.1997.03540420048028.PubMedCrossRefGoogle Scholar
- 17.Serdarevic N, Serdarevic R, Memic A. Comparison of the performance of three cancer antigen (CA) 15-3 immunoassays. JHSCI 2016;6(3):154–61. https://www.jhsci.ba/OJS/index.php/jhsci/article/view/381.
- 18.Bishop ML, Fody EP, Schoeff LE. Clinical chemistry: techniques, principles, correlation. 6rd ed. Philadelphia: Wolters Kluwer Health; 2010. Available from: www.academia.edu/29483806/Clinical_Chemistry_Techniques_Principles_Correlations.
- 19.Roddam AW, Rimmer J, Nickerson C, Ward AM; NHS Prostate Cancer Risk Management Programme. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem. 2006;43(Pt 1):35–48. https://doi.org/10.1258/000456306775141731.
- 20.Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11–79. https://doi.org/10.1373/clinchem.2008.105601.PubMedCrossRefGoogle Scholar
- 25.Kort S, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006;52:1568–74. https://doi.org/10.1373/clinchem.2006.069039.PubMedCrossRefGoogle Scholar
- 27.Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schröder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int. 2001;88:545–50. https://doi.org/10.1046/j.1464-410X.2001.02374.x.PubMedCrossRefGoogle Scholar
- 28.Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006;52(1):59–64. https://doi.org/10.1373/clinchem.2005.059170 Published 2006.PubMedCrossRefGoogle Scholar